Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples

Journal of Clinical Virology

Volumn 101, Issue , 2018, Pages 69-73

  Asciutto, Katrin Christine ^a   Ernstson, Avalon ^a   Forslund, Ola ^a   Borgfeldt, Christer ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

HPV analyses; HPV mRNA; Self collected vaginal smear; Urinary sample

Indexed keywords

MESSENGER RNA; VIRUS RNA;

ADENOCARCINOMA IN SITU; ADULT; AGED; ARTICLE; BIOPSY; CANCER SCREENING; COLPOSCOPY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOOP ELECTROSURGICAL EXCISION PROCEDURE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; SCREENING; SELF SAMPLING; SENSITIVITY AND SPECIFICITY; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; URINE SAMPLING; UTERINE CERVIX; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; VAGINA SMEAR; VIRUS DETECTION; WART VIRUS; CARCINOMA IN SITU; CYTOLOGY; EARLY CANCER DIAGNOSIS; GENETICS; ISOLATION AND PURIFICATION; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; SPECIMEN HANDLING; URINE; UTERINE CERVIX CARCINOMA IN SITU; VAGINA; VIROLOGY; YOUNG ADULT;

ADULT; AGED; CARCINOMA IN SITU; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; URINE; VAGINA; YOUNG ADULT;

EID: 85041539502     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2018.02.002     Document Type: Article

References (41)

1. WHO, Human Papillomavirus (HPV) and Cervical Cancer [Internet Page]. 2018, World Health Organization [updated June 2016; cited 2017 Feb 22]. Available from: http://www.who.int/mediacentre/factsheets/fs380/en/.
2. Andrae, B., Kemetli, L., Sparen, P., Silfverdal, L., Strander, B., Ryd, W., et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J. Natl. Cancer Inst. 100:9 (2008), 622–629.
3. Nationellt Kvalitetsregister för Cervixcancerprevention [Web page]. 2018 [cited 2018 Jan 11]. Available from: http://www.nkcx.se/.
4. Walboomers, J.M., Jacobs, M.V., Manos, M.M., Bosch, F.X., Kummer, J.A., Shah, K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:1 (1999), 12–19.
5. Arbyn, M., Tommasino, M., Depuydt, C., Dillner, J., Are 20 human papillomavirus types causing cervical cancer?. J. Pathol. 234:4 (2014), 431–435.
6. Lowy, D.R., Solomon, D., Hildesheim, A., Schiller, J.T., Schiffman, M., Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 113:Suppl. 7 (2008), 1980–1993.
7. Ostor, A.G., Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 12:2 (1993), 186–192.
8. Cuzick, J., Clavel, C., Petry, K.U., Meijer, C.J., Hoyer, H., Ratnam, S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119:5 (2006), 1095–1101.
9. Burd, E.M., Human papillomavirus laboratory testing: the changing paradigm. Clin. Microbiol. Rev. 29:2 (2016), 291–319.
10. Arbyn, M., Snijders, P.J., Meijer, C.J., Berkhof, J., Cuschieri, K., Kocjan, B.J., et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?. Clin. Microbiol. Infect. 21:9 (2015), 817–826.
11. Cuzick, J., Cadman, L., Mesher, D., Austin, J., Ashdown-Barr, L., Ho, L., et al. Comparing the performance of six human papillomavirus tests in a screening population. Br. J. Cancer 108:4 (2013), 908–913.
12. Reid, J.L., Wright, T.C. Jr., Stoler, M.H., Cuzick, J., Castle, P.E., Dockter, J., et al. Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study. Am. J. Clin. Pathol. 144:3 (2015), 473–483.
13. Haedicke, J., Iftner, T., A review of the clinical performance of the Aptima HPV assay. J. Clin. Virol. 76:Suppl. 1 (2016), S40–S48.
14. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr. Eval. Carcinog. Risks Hum. 100:Pt B (2012), 255–313.
15. Arbyn, M., Ronco, G., Anttila, A., Meijer, C.J., Poljak, M., Ogilvie, G., et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30:Suppl. 5 (2012), F88–99.
16. Nelson, E.J., Hughes, J., Oakes, J.M., Thyagarajan, B., Pankow, J.S., Kulasingam, S.L., Human papillomavirus infection in women who submit self-collected vaginal swabs after internet recruitment. J. Community Health 40:3 (2015), 379–386.
17. Solomon, D., Davey, D., Kurman, R., Moriarty, A., O'Connor, D., Prey, M., et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287:16 (2002), 2114–2119.
18. Darragh, T.M., The LAST project and the diagnostic bottom line. Cytopathology 26:6 (2015), 343–345.
19. Nieves, L., Enerson, C.L., Belinson, S., Brainard, J., Chiesa-Vottero, A., Nagore, N., et al. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection. Int. J. Gynecol. Cancer 23:3 (2013), 513–518.
20. Ting, J., Mugo, N., Kwatampora, J., Hill, C., Chitwa, M., Patel, S., et al. High-risk human papillomavirus messenger RNA testing in physician- and self-collected specimens for cervical lesion detection in high-risk women, Kenya. Sex. Transm. Dis. 40:7 (2013), 584–589.
21. Belinson, J.L., Qiao, Y.L., Pretorius, R.G., Zhang, W.H., Rong, S.D., Huang, M.N., et al. Shanxi Province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. Int. J. Gynecol. Cancer 13:6 (2003), 819–826.
22. Wright, T.C. Jr., Denny, L., Kuhn, L., Pollack, A., Lorincz, A., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 283:1 (2000), 81–86.
23. Zhao, F.H., Lewkowitz, A.K., Chen, F., Lin, M.J., Hu, S.Y., Zhang, X., et al. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method. J. Natl. Cancer Inst. 104:3 (2012), 178–188.
24. Arbyn, M., Verdoodt, F., Snijders, P.J.F., Verhoef, V.M.J., Suonio, E., Dillner, L., et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. The Lancet Oncology 15:2 (2014), 172–183.
25. Belinson, J.L., Du, H., Yang, B., Wu, R., Belinson, S.E., Qu, X., et al. Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing. Int. J. Cancer 130:8 (2012), 1855–1860.
26. Dijkstra, M.G., Heideman, D.A., van Kemenade, F.J., Hogewoning, K.J., Hesselink, A.T., Verkuijten, M.C., et al. Brush-based self-sampling in combination with GP5+/6+-PCR-based hrHPV testing: high concordance with physician-taken cervical scrapes for HPV genotyping and detection of high-grade CIN. J. Clin. Virol. 54:2 (2012), 147–151.
27. Bhatla, N., Dar, L., Patro, A.R., Kumar, P., Kriplani, A., Gulati, A., et al. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?. Cancer Epidemiol. 33:6 (2009), 446–450.
28. Holanda, F. Jr., Castelo, A., Veras, T.M., de Almeida, F.M., Lins, M.Z., Dores, G.B., Primary screening for cervical cancer through self sampling. Int. J. Gynaecol. Obstet. 95:2 (2006), 179–184.
29. Belinson, J.L., Hu, S., Niyazi, M., Pretorius, R.G., Wang, H., Wen, C., et al. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: implications for vaginal self-collection. Int. J. Cancer 127:5 (2010), 1151–1157.
30. Pathak, N., Dodds, J., Zamora, J., Khan, K., Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ, 349, 2014, g5264.
31. Leeman, A., Del Pino, M., Molijn, A., Rodriguez, A., Torne, A., de Koning, M., et al. HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable to a physician-taken smear or brush-based self-sample: cross-sectional data from a triage population. BJOG 124:August (9) (2017), 1356–1363.
32. Senkomago, V., Des Marais, A.C., Rahangdale, L., Vibat, C.R., Erlander, M.G., Smith, J.S., Comparison of urine specimen collection times and testing fractions for the detection of high-risk human papillomavirus and high-grade cervical precancer. J. Clin. Virol. 74 (2016), 26–31.
33. Cuschieri, K., Nandwani, R., McGough, P., Cook, F., Hogg, L., Robertson, C., et al. Urine testing as a surveillance tool to monitor the impact of HPV immunization programs. J. Med. Virol. 83:11 (2011), 1983–1987.
34. Jong, E., Mulder, J.W., van Gorp, E.C., Wagenaar, J.K., Derksen, J., Westerga, J., et al. The prevalence of human papillomavirus (HPV) infection in paired urine and cervical smear samples of HIV-infected women. J. Clin. Virol. 41:2 (2008), 111–115.
35. Daponte, A., Pournaras, S., Mademtzis, I., Hadjichristodoulou, C., Kostopoulou, E., Maniatis, A.N., et al. Evaluation of high-risk human papillomavirus types PCR detection in paired urine and cervical samples of women with abnormal cytology. J. Clin. Virol. 36:3 (2006), 189–193.
36. Stanczuk, G., Baxter, G., Currie, H., Lawrence, J., Cuschieri, K., Wilson, A., et al. Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study). BMJ Open, 6(4), 2016, e010660.
37. Darlin, L., Borgfeldt, C., Forslund, O., Henic, E., Hortlund, M., Dillner, J., et al. Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening. J. Clin. Virol. 58:1 (2013), 155–160.
38. Enerly, E., Bonde, J., Schee, K., Pedersen, H., Lonnberg, S., Nygard, M., Self-sampling for human papillomavirus testing among non-attenders increases attendance to the norwegian cervical cancer screening programme. PLoS One, 11(4), 2016, e0151978.
39. Harper, D.M., Longacre, M.R., Noll, W.W., Belloni, D.R., Cole, B.F., Factors affecting the detection rate of human papillomavirus. Ann. Fam. Med. 1:4 (2003), 221–227.
40. Kitchener, H.C., Almonte, M., Gilham, C., Dowie, R., Stoykova, B., Sargent, A., et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol. Assess. 13:51 (2009), 1–150 iii–iv.
41. Sankaranarayanan, R., Nene, B.M., Shastri, S.S., Jayant, K., Muwonge, R., Budukh, A.M., et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med., 360(14), 2009.